One of the purposes of the congress, which took place on July 6-8, 2023, in Munich, is to stimulate the exchange of experience between clinicians from different medical disciplines and service providers in the health care system. German Key Opinion Leaders presented results of the PULSE study based on the final data set at the congress.

NeoDynamics’ PULSE study is a German prospective multicenter study (ClinicalTrials.gov ID: NCT03975855) designed to document the performance of the NeoNavia biopsy device in the axillary lymph nodes on 138 enrolled patients. Professor Marc Thill, from Agaplesion Markus Krankenhaus, Frankfurt, has been principal investigator, and presented a poster on the study results. Additionally, Dr. Stefan Paepke, from TU Munich r.d. Isar presented the PULSE data during a scientific session on “Minimally-invasive Diagnostics and Therapy” on the last day.

The study has demonstrated that pneumatic pulses promoted high needle control and stabilization of target lesions during insertion of the needle and that it was possible to obtain multiple samples with a single insertion.

“We want to and need to perform fewer surgeries and more minimally-invasive procedures in breast cancer patients. That concerns the tumor in the breast and the associated axillary lymph nodes. The data once again shows that NeoNavia is a valuable tool supporting this development,” says Dr. Stefan Paepke.